Relay Therapeutics, Inc. (RLAY)
16.07
+0.16
(+1.01%)
USD |
NASDAQ |
Nov 20, 11:00
Relay Therapeutics Cash from Operations (Quarterly) : -63.93M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -63.93M |
| June 30, 2026 | -54.11M |
| March 31, 2026 | -51.11M |
| December 31, 2025 | -44.86M |
| September 30, 2025 | -62.12M |
| June 30, 2025 | -55.26M |
| March 31, 2025 | -73.21M |
| December 31, 2024 | -57.87M |
| September 30, 2024 | -75.08M |
| June 30, 2024 | -65.83M |
| March 31, 2024 | -50.32M |
| December 31, 2023 | -89.19M |
| September 30, 2023 | -75.40M |
| June 30, 2023 | -68.60M |
| March 31, 2023 | -67.13M |
| December 31, 2022 | -57.08M |
| Date | Value |
|---|---|
| September 30, 2022 | -66.14M |
| June 30, 2022 | -57.09M |
| March 31, 2022 | -49.17M |
| December 31, 2021 | -39.71M |
| September 30, 2021 | -53.20M |
| June 30, 2021 | -28.14M |
| March 31, 2021 | 46.64M |
| December 31, 2020 | -35.27M |
| September 30, 2020 | -24.04M |
| June 30, 2020 | -20.84M |
| March 31, 2020 | -22.33M |
| December 31, 2019 | -22.76M |
| September 30, 2019 | -17.50M |
| June 30, 2019 | -15.05M |
| March 31, 2019 | -10.82M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -5.94M |
| TG Therapeutics, Inc. | 45.23M |
| Spyre Therapeutics, Inc. | -77.80M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 62.37M |
| Cash from Financing (Quarterly) | 4.42M |
| Free Cash Flow | -214.02M |
| Free Cash Flow Per Share (Quarterly) | -0.2917 |
| Free Cash Flow to Equity (Quarterly) | -60.31M |
| Free Cash Flow to Firm (Quarterly) | -63.93M |
| Free Cash Flow Yield | -6.07% |